Corvus Pharmaceuticals (CRVS) Change in Cash (2015 - 2026)

Corvus Pharmaceuticals' Change in Cash history runs 12 years deep, the most recent figure standing at $35.5 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 1049.64% year-over-year to $35.5 million in Q1 2026; TTM through Mar 2026 was $35.1 million, a 1528.69% increase from a year earlier, with the FY2025 full-year figure at -$4.2 million, down 7.32% from the prior year.
• Change in Cash climbed to $35.5 million in Q1 2026 per CRVS's latest filing, from $1.7 million in the prior quarter.
• Across five years, Change in Cash topped out at $35.5 million in Q1 2026 and bottomed at -$32.0 million in Q1 2022.
• The 5-year median for Change in Cash is -$3.5 million (2023), against an average of -$1.4 million.
• Across the five-year window, Change in Cash plunged 211.69% in 2022 and surged 1049.64% in 2026, its largest moves.
• Year by year, Change in Cash stood at -$11.4 million in 2022, then jumped by 34.51% to -$7.5 million in 2023, then jumped by 154.24% to $4.1 million in 2024, then sank by 57.91% to $1.7 million in 2025, then surged by 1978.76% to $35.5 million in 2026.
• Per Business Quant, the three latest CRVS Change in Cash figures stand at $35.5 million (Q1 2026), $1.7 million (Q4 2025), and -$11.8 million (Q3 2025).